Jon Burrows, CEO of Oxford Biodynamics
Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology.
Any seasoned investor will tell you that investing in biotechnology companies comes with an exhilarating balance of risk and reward. If a company is successful in getting its products to market, there is potential for significant investment gains. The complex nature of biotech, and the highly regulated environment in which it operates, can make it difficult for investors to assess the probability of a company’s success.
How do investors measure value in biotechs? The first element investors typically consider is a company’s technology. Is it promising? Is it a discovery made by a well-known and respected institution? Will it solve a problem or change lives for the better? Does it have a good chance of achieving commercial success?
A second measure of value for many investors, often including the most seasoned investors, is a significant market opportunity and a compelling story. OBD’s story is focused on improving outcomes for cancer patients, but also features value drivers – such as its partnerships with leading institutions, collaborations with pharma, strong technology portfolio, commercially available tests for precision medicine and a unique 3D genomic knowledgebase – that will pique investor interest.